# No-Antibiotics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/no-antibiotics

- Industry: Biotechnology
- Headquarters: Qingdao, China
- Website: www.phageseeker.com
- Total disclosed funding: $18M
- Latest round: Series B (Mar 1, 2023)
- Investors on record: 6

## About

Established in 2017 and based in Qingdao, China, No-Antibiotics is a provider of integrated solutions for phage resistant bacteria, currently serving the animal, fruit and vegetable, and human health sectors. At the same time, the company is the head company of alternative resistance solutions in the domestic animal protection field, and has established the largest enterprise-level phage library in China. The company's R&D team has 26 masters, 7 PhDs and 6 contracted special experts, and has established long-term cooperation with Beijing University of Chemical Technology, China Ocean University and other institutions. As of August 2022, the company has obtained 21 invention patents and 78 bacteriophage strain preservation certificates.

The company mainly develops phage preparations, targeting bacteria with high morbidity and serious drug resistance that cause animal sickness in agriculture and animal husbandry, including Staphylococcus, Salmonella, etc. The company's products are divided into animal, aquatic, pet and feed additives segments, specifically Noanso Clear, Noansa, etc.

## Funding rounds

- Series B, Mar 1, 2023, $14M — 5Y Capital, Cenova Ventures, Hyfinity Investments, HosenCare Brothers
- Series A, May 22, 2019, $2.9M — Milestone Capital, Qingsong Fund, Hyfinity Investments
- Angel, Dec 31, 2017, $1.1M — Hyfinity Investments

## Investors

- Hyfinity Investments (https://capitalatlas.ai/funds/hyfinity-investments) — Angel, Series A, Series B
- Milestone Capital — Series A
- Qingsong Fund (https://capitalatlas.ai/funds/qingsong-fund) — Series A
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series B
- Cenova Ventures (https://capitalatlas.ai/funds/cenova-ventures) — Series B
- HosenCare Brothers (https://capitalatlas.ai/funds/hosencare-brothers) — Series B